Inmune Bio Inc Stock Price, News & Analysis

INmune Bio reported its Q1 2021 financial results and provided key business updates. The company is progressing in its Phase I trial of XPro1595 for Alzheimer's disease, showing promising interim results that support a Phase II trial later this year. Additionally, they began screening for a Phase I trial of INKmune for high-risk myelodysplastic syndrome. Financially, INmune raised approximately $29 million through an ATM agreement, but recorded a net loss of $4.6 million for the quarter. The company has $45.3 million in cash with no debt.

INmune Bio (NASDAQ: INMB) will host a conference call on May 5, 2021, at 4:30 PM ET, to discuss its first-quarter results for the period ending March 31, 2021, and provide a corporate update. The call can be accessed by dialing 1-877-407-0784 (or 1-201-689-8560 for international callers). A transcript will be available shortly after the call, with a replay accessible until May 12, 2021.

INmune Bio focuses on developing treatments targeting the innate immune system for various diseases.

INmune Bio, Inc. (NASDAQ: INMB) announced a participation by CEO Raymond J. Tesi, MD, in a fireside chat at the B Riley Neuroscience Conference scheduled for April 28, 2021, at 1:00 PM ET. The company focuses on developing therapies that leverage the innate immune system to combat diseases, with product platforms addressing conditions such as COVID-19, cancer, Alzheimer’s, and NASH. The event will provide an opportunity for investors to engage in virtual one-on-one meetings with the company.

INmune Bio, Inc. (NASDAQ: INMB) announced that Professor Mark Lowdell, PhD, will present at two medical meetings: the Innate Killer Digital Summit and the Festival of Biologics USA. At the Innate Killer Summit, he will discuss new findings on INKmune™, an NK-cell priming immunotherapy, which enhances the ability of NK cells to target tumors, showing superior activity compared to traditional cytokine approaches. The second presentation at the World Immunotherapy Congress will focus on improving NK-tumor cell interactions. Both events are crucial for showcasing INmune Bio's advancements in cancer immunotherapy.

INmune Bio, Inc. (NASDAQ: INMB) announced its participation in two virtual investor conferences in March 2021. The 33rd Annual Roth Virtual Conference will feature a panel discussion on therapeutics against SARS-CoV-2 on March 15, 2021, at 12:00 PM ET. The Oppenheimer 31st Annual Healthcare Conference will include a presentation by INmune Bio on March 16, 2021, at 1:10 PM ET. Interested individuals can register for both events through provided links.

INmune Bio is focused on developing treatments that leverage the innate immune system to combat diseases like COVID-19, cancer, Alzheimer’s, and NASH.

INmune Bio, Inc. (NASDAQ: INMB) reported its financial results for the year ending December 31, 2020. The company announced a net loss of approximately $12.1 million, a rise from $7.7 million in 2019. Research expenses totaled $5.9 million, while administrative costs were $6.3 million. Highlights include interim Phase 1b data showing that XPro1595 reduced neuroinflammation in Alzheimer's patients. The company raised $28.4 million through an ATM facility, strengthening its balance sheet. Upcoming milestones include Phase 2 studies for XPro1595 and Quellor.

INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for March 4, 2021 at 4:30 PM ET to discuss its fourth quarter and full year 2020 results. The company is focused on harnessing the innate immune system to develop treatments for various diseases, including COVID-19, cancer, Alzheimer's, and NASH. The call can be accessed via dial-in or a live webcast, with a replay available until March 11, 2021.

For more information about INmune Bio, visit www.inmunebio.com.

INmune Bio (NASDAQ: INMB) has released interim data from its Phase 1b trial showing that XPro1595 significantly reduces neuroinflammation and improves biomarkers in Alzheimer’s disease patients after three months of therapy. Key results indicate decreased CSF levels of neuroinflammatory markers with p-values less than 0.0001, while MRI findings suggest notable neuroimaging improvements. The company plans to initiate a blinded randomized Phase 2 study before the end of the year. A Key Opinion Leader webinar is scheduled for January 21, 2021, to discuss these findings in detail.

INmune Bio, Inc. (NASDAQ: INMB) announces a Key Opinion Leader (KOL) webinar on January 21, from 8:00 AM – 9:00 AM ET, to showcase expanded biomarker results from its Phase 1b clinical trial of XPro1595, targeting neuroinflammation in Alzheimer's patients. The trial aims to demonstrate a reduction in neuroinflammation through XPro1595, with updates presented by key experts including RJ Tesi, M.D., and Dr. CJ Barnum. The company previously noted a decrease in neuroinflammation as measured by the novel biomarker white matter free water (WMFW).